CAS:1379545-95-5M2698

您的位置 : 首页 / MAPK/ERK Pathway / RSK & Akt / M2698

M2698 M2698 Cat No. FB09915Cas No. 1379545-95-5

Synonyms: M2698;HTI-286 HCl;SPA 110 HCl

MSC2363318A, also known as M2698, is an orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.2229 mL
- 11.1146 mL
- 22.2291 mL
- 5 mM
- 0.4446 mL
- 2.2229 mL
- 4.4458 mL
- 10 mM
- 0.2223 mL
- 1.1115 mL
- 2.2229 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号	1379545-95-5	储存条件	粉末 -20°C 3 年液体 -80°C 12 月
分子式	C21H19ClF3N5O	运输	蓝冰
分子量	449.86	别名	M2698;HTI-286 HCl;SPA 110 HCl

靶点数据

生物活性

描述MSC2363318A, also known as M2698, is an orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, p70S6K/Akt inhibitor MSC2363318A binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase.